Australia's Cynata Therapeutics up on starting analysis for wound dressing product

Cynata Therapeutics

28/12/2023 03:01

** Shares of Cynata Therapeutics Ltd  CYP.AX  rise as much
as 4.2% to A$0.125, their highest level since Dec. 13
    ** Biotechnology co initiates analysis of wound surface area
for 16 patients for testing its CYP-006TK product in patients
with diabetic foot ulcer 
    ** The analysis is part of Phase 1 clinical trial of the
CYP-006TK
    ** CYP-006TK is a wound dressing product candidate being
developed by co 
    ** Co anticipates receiving initial results in Q1 2024
    ** Stock down 60% this year, as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))